Business
PetLife Pharmaceuticals Adds Seasoned Medical Professionals to the Management Team
PetLife Pharmaceuticals Adds Seasoned Medical Professionals to the Management Team.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, July 25, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the additions of Dr. Joel Beth Mitchel-Navratik, Vice President of Veterinary Affairs, and Dr. Vivek Ramana, Chief Medical Officer, to the management team.\n Dr. Joel Beth Mitchel-Navratik   Vice President of Veterinary Affairs Dr. Mitchell-Navratik holds a Bachelor of Science Degree in Zoology and a Doctorate in Veterinary Medicine from the University of Florida.  After university, she undertook an internship in Small Animal Medicine and Surgery at The Animal Medical Center and Bobst Hospital in New York City in 1994. Those same years, she joined the Aventura Animal Hospital and was soon promoted to the position of Chief of Staff within the facility. This is a position she has held since then. One of her biggest achievements at the facility has been to expand Aventura Animal Hospital to a full service hospital with an emergency care unit that is open 24 hours a day, 7 days a week. Since 2001, Dr. Joel Beth Mitchell Navratik has served as the Corporate Medical Director for Pet Medical Centers, LLC. in South Florida. Pet Medical Centers is comprised of 8 state of the art small animal veterinary hospitals employing 27 veterinarians and 162 staff members. Pet Medical Centers offers a comprehensive approach to Veterinary Care, which includes internal medicine, surgery, radiology, ultrasound, CT imaging, boarding, grooming, preventive medicine and a fully stocked pharmacy. Pet Medical Centers is the largest privately held group of veterinary hospitals in the Unites States. Dr. Mitchel-Navratik has used Escozine for Pets in her clinical practice and has observed its therapeutic benefit firsthand. Dr. Mitchel-Navratik will be responsible for liaison with the professional veterinary community and will lead the clinical portion of our upcoming FDA trials. “Veterinary Medicine is in need of an alternative all natural affordable oncologic (cancer) treatment that is safe for our pets. The Escozine for Pets FDA trials will soon be starting, providing the data we need to support our anecdotal trials that we have seen success with so far. I look forward to sharing the results with ...